Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms

Objective To assess the impact of baseline body mass index (BMI) on the outcomes of patients with neuroendocrine neoplasms (NENs) in a population-based setting. Methods Linked provincial administrative databases (within the province of Alberta, Canada), 2004–2019, were accessed, and patients with NENs and complete information about BMI near the time of diagnosis were reviewed. The impact of BMI on overall survival was evaluated through the use of Kaplan–Meier survival estimates and multivariable Cox regression modeling. Results A total of 1010 patients with NENs and BMI information were included. Using Kaplan–Meier survival estimates, survival outcomes were best with individuals with obesity and were worst with underweight individuals ( P